Can above-optimal glucose, triglycerides, and low HDL reflect insulin resistance?

The presentation of elevated fasting glucose and triglycerides (TG) alongside low high-density lipoprotein (HDL) cholesterol represents a classic metabolic signature highly indicative of underlying insulin resistance.

Clinical Utility of the Lipid Triad

• Surrogate Markers: This biomarker triad forms the foundation of validated clinical indices, including the TG/HDL ratio, the triglyceride-glucose (TyG) index, and the Metabolic Score for Insulin Resistance (METS-IR).
• Diagnostic Power: The TyG index and TG/HDL ratio correlate strongly with the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), offering comparable or superior sensitivity in identifying metabolic syndrome. However, clinicians should note that the TG/HDL ratio is less reliable in certain populations, such as African American cohorts.

Molecular Mechanisms of Insulin Impairment

• Signaling Disruption: Adipose-derived pro-inflammatory cytokines, primarily TNF-α and IL-6, activate key intracellular stress kinases, specifically c-Jun N-terminal kinase (JNK) and IκB kinase beta (IKKβ).
• IRS-1 Inhibition: These kinases catalyze the inhibitory serine phosphorylation of Insulin Receptor Substrate-1 (IRS-1) at Ser312 (Ser307 in rodents) and upregulate SOCS3. This blocks insulin receptor-IRS-1 coupling, targets IRS-1 for proteasomal degradation, and blunts downstream PI3K/AKT signaling, ultimately preventing GLUT4 translocation and glucose uptake.

Promotion of Hepatic Lipogenesis

• Transcriptional Activation: Adipose-derived cytokines suppress AMPK and activate the master transcription factors SREBP-1c and ChREBP. This directly upregulates key lipogenic enzymes, including fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase-1 (SCD1).
• Substrate Overload: Elevated cytokines simultaneously trigger adipocyte lipolysis, accelerating the flux of free fatty acids to the liver to fuel de novo lipogenesis and triglyceride production.

Bottom line

• The glucose-triglyceride-HDL triad serves as a robust clinical surrogate for insulin resistance, biochemically driven by a pathological cascade where adipose-derived cytokines simultaneously impair systemic insulin signaling (via JNK/IRS-1 inhibition) and accelerate hepatic triglyceride synthesis (via SREBP-1c/ChREBP activation).